← Back to Clinical Trials
Recruiting NCT06385340

Investigation of the Effect of Lipikar Baume AP+M

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Actinic Keratoses
Sponsor CentroDerm GmbH
Study Type INTERVENTIONAL
Phase N/A
Enrollment 20
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-04-23
Completion 2025-10-30
Interventions
Lipikar Baume AP+M

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two arms according to a randomization scheme The purpose of this study is to observe the skin barrier function, transepidermal water loss and microbial changes in study participants with actinic field damage of both arms. It's a randomized, evaluator blinded, intra-individual controlled study conducted in one center in Germany, in adult subjects having AK (grade I to III) lesions on the forearms and back of hands and meeting specific inclusion/exclusion criteria. A total of 20 subjects will be enrolled. The study design consists in 4-week evaluation period, with 2 visits per subject: Screening/Baseline (Day 0, Day 28 (end of Lipikar Baume AP+M application)).

Eligibility Criteria

Inclusion Criteria: * Male, female, diverse persons (\> 18yo) who are capable of giving consent * Female patients are eligible if the subject is not a woman of childbearing potential (WOCBP) or if she is postmenopausal (cessation of menstruation \>12 months) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, total hysterectomy) * Signed informed consent * Diagnosis of at least 4 actinic keratoses of the the forearm and/or back of the hand (each arm) * Olsen grade I, II and/or III * Subjects with similar severity and number of AKs on each side symmetrically * The study participant is in good general condition for his or her age and does not currently have any active diseases that, in the opinion of the investigator, justify exclusion from the study Exclusion Criteria: * Known or documented intolerance to any of the ingredients of Lipikar Baume AP+M * Any planned AK treatment during the study * Treatment of actinic keratoses in the application area within the past 3

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}